Tomorrow’s challenge is to develop new medicines that can prevent or cure currently incurable diseases. Today’s challenge is to get to tomorrow – and that’s a tall order in itself.

Rising customer expectations: The commercial environment is getting harsher, as healthcare payers impose new cost constraints on healthcare providers and scrutinise the value medicines offer much more carefully. They want new therapies that are clinically and economically better than the existing alternatives, together with hard, real-world outcomes data to back any claims about a medicine’s superiority.

Poor scientific productivity: Pharma’s output has remained at a stable level for the past decade. Using the same discovering and developing processes, there’s little reason to think its productivity will suddenly soar.

Cultural sclerosis: The prevailing management culture, mental models and strategies on which the industry relies are the same ones it’s traditionally relied on, even though they’ve been eclipsed by new ways of doing business.

Mike Swanick
Global Pharmaceuticals and Life Sciences leader
Tel: +1 (267) 330 6060
Douglas Strang
Global Pharmaceuticals and Life Sciences Advisory Leader
Tel: +1 (267) 330 3045
Anthony Farino
Growth markets leader
Pharmaceuticals & life sciences
Tel: +1 (312) 298 2631